293 related articles for article (PubMed ID: 31629162)
1. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
Lv X; Yang X; Zhan MM; Cao P; Zheng S; Peng R; Han J; Xie Z; Tu Z; Liao C
Eur J Med Chem; 2019 Dec; 184():111769. PubMed ID: 31629162
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold.
Zhan MM; Yang Y; Luo J; Zhang XX; Xiao X; Li S; Cheng K; Xie Z; Tu Z; Liao C
Eur J Med Chem; 2018 Jan; 143():724-731. PubMed ID: 29220793
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
Chen DX; Huang J; Liu M; Xu YG; Jiang C
Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a hydrazone moiety as potent PLK1 inhibitors.
Li Z; Xu L; Zhu L; Zhao Y; Hu T; Yin B; Liu Y; Hou Y
Bioorg Med Chem Lett; 2020 Aug; 30(16):127329. PubMed ID: 32631534
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
7. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
Chapagai D; Ramamoorthy G; Varghese J; Nurmemmedov E; McInnes C; Wyatt MD
J Med Chem; 2021 Jul; 64(14):9916-9925. PubMed ID: 34210138
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
11. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
[TBL] [Abstract][Full Text] [Related]
12. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
Kumar M; Pydi SP; Sharma S; Singh TP; Kaur P
J Mol Graph Model; 2014 Jun; 51():104-12. PubMed ID: 24879322
[TBL] [Abstract][Full Text] [Related]
13. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
14. Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1.
Sun J; Liu HY; Xu RF; Zhu HL
Bioorg Med Chem; 2017 Dec; 25(24):6581-6588. PubMed ID: 29100732
[TBL] [Abstract][Full Text] [Related]
15. Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors.
Sun J; Lv PC; Guo FJ; Wang XY; Xiao-Han ; Zhang Y; Sheng GH; Qian SS; Zhu HL
Eur J Med Chem; 2014 Jun; 81():420-6. PubMed ID: 24859762
[TBL] [Abstract][Full Text] [Related]
16. Polo-like kinases inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2012; 19(23):3937-48. PubMed ID: 22709006
[TBL] [Abstract][Full Text] [Related]
17. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
[TBL] [Abstract][Full Text] [Related]
18. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
[TBL] [Abstract][Full Text] [Related]
19. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
Strebhardt K; Becker S; Matthess Y
Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
